The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice
Salar, Antonio × Haioun, Corinne Rossi, Francesca G Duehrsen, Ulrich Pettengell, Ruth Johnsen, Hans E Jaeger, Ulrich Verhoef, Gregor Schwenkglenks, Matthias Bacon, Pamela Bendall, Kate Lugtenburg, Pieternella J #
Leukemia Research vol:36 issue:5 pages:548-553
Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high-and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery. (C) 2012 Elsevier Ltd. All rights reserved.